LenioBio and Fraunhofer Institute IME have entered a licensing agreement, allowing LenioBio to commercialize technology into a protein expression platform.
Pall Corporation has launched a monoclonal antibody clarification platform without centrifugation or process additives to support cell cultures of up to 2,000L.
Cell therapy developers can source “regulator ready” stem cells from the UK Stem Cell Bank (UKSCB) for a £500 per vial fee under a scheme announced by the MHRA.
A human plasma protein could make producing pluripotent stem cells cheaper and faster according to academics in the UK and Sweden and partner GE Healthcare.
The shelf life of a cell therapy product is crucial in determining a firm’s manufacturing strategy according to the makers of the first approved stem-cell based drug.
In what may be an early indication of states looking to get more involved in biologic development, EMD Millipore has won a $400,000 grant from the Massachusetts Life Sciences Center (MLSC) to fund a partnership with Promethera Biosciences.
CellCura has inked an agreement with IDT Biologika for the testing and adaptation of its protein-free (PF) media for the production of cell lines for vaccine manufacturing.
Sheffield Bio-Science takes on responsibility for global sales, distribution and development of Girus Life Sciences’ chemically defined Regocel supplements.
Crucell and DSM Biologics have added fellow Dutch firm Bioceros to the PER.C6 vendor network to provide manufacturing and support capacity in line with increased demand for the cell line.
Genetix Limited has launched the ClonePixFL, a mammalian cell
imaging and picking instrument that builds upon the success of the
ClonePix adding fluorescent capabilities to its clone picking
abilities.
